Neurotensin: an endogenous antipsychotic?
Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.
Kinkead
Becky
B
Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Suite 4000 Woodruff Memorial Research Building, 1639 Pierce Drive, Atlanta, Georgia 30322, USA.
Nemeroff
Charles B
CB
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009496:Neurotensin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D009496:Neurotensin